KDM3A and neoplasm: JMJD1A inhibition overcame resistance to antiangiogenic treatments and enhanced antitumor effects.[62] In addition, epigenetic modification of tumor cells could control the recruitment and infiltration of TAMs by regulating pro‐inflammatory cytokine and chemokine pathways.